8-K: Avalo Therapeutics Advances AVTX-009 for Hidradenitis Suppurativa with Promising Clinical Data and Extended Cash Runway

Avalo Therapeutics is progressing its AVTX-009 program for Hidradenitis Suppurativa (HS), supported by clinical evidence and a cash runway extending into 2027.

Summary

• Avalo Therapeutics is focused on developing AVTX-009, a highly potent IL-1 inhibitor, for the treatment of Hidradenitis Suppurativa (HS) and other autoimmune diseases.
• The company's lead drug candidate, AVTX-009, has shown a strong pharmacokinetic profile with a half-life of approximately 19 days and high potency compared to other IL-1 inhibitors.
• Avalo is initiating the Phase 2 LOTUS trial for AVTX-009 in HS, with the first patient enrollment expected in the second half of 2024.
• The company believes that IL-1 is a key driver in the pathophysiology of HS, supported by clinical evidence from other trials, including a Phase 2 trial of lutikizumab.
• The global HS market is estimated to have a potential of over $9.5 billion, with a significant unmet need for effective treatments.
• Avalo has a cash balance of $93.4 million as of June 30, 2024, and expects its cash runway to extend into 2027.
• The company is also exploring the potential of AVTX-009 in other autoimmune diseases, such as Inflammatory Bowel Disease (IBD).

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Avalo, highlighting the potential of AVTX-009 and the company's financial stability. However, there are inherent risks associated with clinical development, which temper the overall sentiment.

Positives

• AVTX-009 has a high potency and favorable half-life, potentially allowing for improved efficacy and convenient dosing.
• The company has a strong cash position with a runway into 2027.
• The Phase 2 LOTUS trial is well-designed with a primary endpoint of HiSCR75 at 16 weeks.
• Avalo is targeting a large and underserved market with significant growth potential.
• The company has an experienced management team with a track record of success in pharma and biotech.

Negatives

• Some clinical evidence suggests that anti-IL-1 therapy may not be effective in HS, as seen in the bermekimab trials.
• The company is still in the early stages of clinical development for AVTX-009.
• The success of the Phase 2 LOTUS trial is not guaranteed, and there are risks associated with clinical trials.

Risks

• Clinical trial results may not be positive, and the drug may not achieve its primary endpoint.
• Regulatory approvals may be delayed or not granted.
• The company may face competition from other companies developing treatments for HS.
• The company's cash runway may not be sufficient to complete all development programs.
• There are general economic and market risks, including those caused by the war in Ukraine and the Middle East.

Future Outlook

Avalo expects to initiate the Phase 2 LOTUS trial in HS and explore the potential of AVTX-009 in other autoimmune diseases, with a cash runway extending into 2027.

Management Comments

• AbbVie plans to evaluate lutikizumab, a dual-variable-domain interleukin (IL) 1/1 antagonist, as monotherapy in UC and in combination with SKYRIZI in Crohn's.
• AbbVie believes lutikizumab has the potential to be used in combinations to provide transformational levels of efficacy in IBD.
• Avalo plans to evaluate combo approaches with lutikizumab and Skyrizi in Crohn's.
• Avalo's Phase 2 studies in IBD are expected to begin later this year.

Industry Context

The development of AVTX-009 aligns with the growing interest in IL-1 inhibition for inflammatory diseases, with other companies also exploring this pathway. The HS market is a significant opportunity with a large unmet need.

Comparison to Industry Standards

• Lutikizumab, another IL-1 inhibitor, showed comparable efficacy to other HS therapies in a Phase 2 trial, despite enrolling a more severe patient population.
• Bermekimab, an IL-1 mAb, failed to demonstrate efficacy in two Phase 2 trials for HS, suggesting that not all IL-1 inhibitors are effective.
• MAS825, a bispecific inhibitor of IL-1 and IL-18, showed positive results in a Phase 2 trial, providing further evidence for the role of IL-1 in HS.
• Avalo's AVTX-009 has a higher potency than Canakinumab and Gevokizumab, suggesting a potential for superior efficacy.

Stakeholder Impact

• Shareholders may benefit from the potential success of AVTX-009 and the company's financial stability.
• Patients with HS may have a new treatment option if AVTX-009 is successful.
• Employees may benefit from the company's growth and success.
• The company's success may have a positive impact on the biotechnology industry.

Next Steps

• Initiate the Phase 2 LOTUS trial for AVTX-009 in HS.
• Enroll the first patient in the Phase 2 LOTUS trial in the second half of 2024.
• Explore the potential of AVTX-009 in other autoimmune diseases, such as IBD.
• Evaluate combo approaches with lutikizumab and Skyrizi in Crohn's.
• Begin Phase 2 studies in IBD later this year.

Key Dates

Keywords

Hidradenitis Suppurativa, AVTX-009, IL-1 inhibitor, autoimmune diseases, clinical trial, LOTUS trial, biologics, inflammation, dermatology, pharmaceuticals